EU and US could reach trade deal this weekend - Reuters
Investing.com -- Celcuity Inc. (NASDAQ:CELC) stock rose 5.2% after the clinical-stage biotechnology company announced it will hold a conference call on Monday, July 28, 2025, to reveal topline results from the PIK3CA Wild-Type Cohort of its Phase 3 VIKTORIA-1 trial.
The Minneapolis-based company will present data from the study evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer. Gedatolisib is a pan-PI3K and mTORC1/2 inhibitor that targets the PAM pathway.
Investors appear optimistic about the upcoming data disclosure, which represents a significant milestone for Celcuity’s oncology pipeline. The company is advancing gedatolisib across multiple clinical trials, positioning it as a potential treatment option for different cancer types.
Beyond the VIKTORIA-1 trial, Celcuity is conducting a Phase 1/2 CELC-G-201 trial evaluating gedatolisib in combination with darolutamide for patients with metastatic castration resistant prostate cancer. Additionally, the company’s Phase 3 VIKTORIA-2 trial is testing gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer patients.
The scheduled conference call will take place at 8:00 AM ET on the announced date, where management is expected to provide detailed insights into the trial outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.